https://doi.org/10.5217/ir.2020.00080 • Intest Res 2021;19(4):386-397



Supplementary Fig. 1. Overall study flow. [a]Patients who had a response to UST IV at week 8, as well as those who did not have a response to placebo IV and who then received UST 6 mg/kg IV at week 8 and had a response at week 16, made up the randomized primary analysis population in the maintenance study; Treatment of UST IV induction for non-responders at week 8 was blinded as patients received both an IV and SC administration with the allocation of active study drug dependent on the patient's original randomization. [b]Patients who had a delayed response to UST induction (nonresponders UST IV and who then received UST SC at week 8 and had a response at week 16) entered the maintenance study but did not undergo randomization. [c]Patients who had a response to placebo IV in the induction study entered the maintenance study but did not undergo randomization; [d]Patients who received UST IV or SC at week 8, but did not have a response at week 16 were discontinued from further participation and entered SFU per protocol. SFU extends 20 weeks after the last dose of UST or placebo. Baseline in the maintenance study is the same as week 8 or week 16 in the induction study, depending on when patients entered maintenance (week 8 or week 16). Overall exposure was 52 weeks or 60 weeks for patients who had a response to UST IV at week 8 or week 16 in the induction study and then completed through maintenance study, respectively. UST, ustekinumab; IV, intravenous; SC, subcutaneous; SFU, safety follow-up; q8w, every 8 weeks; q12w, every 12 weeks.